Tirzepatide vs. Semaglutide: The Complete 2026 Comparison
If you’re considering a GLP-1 program, this is the decision: semaglutide or tirzepatide. They’re the two most prescribed medications in metabolic health, they’re often discussed interchangeably — and they are genuinely different drugs with different mechanisms.
Here’s the complete, hype-free comparison.
The core difference: one receptor vs. two
- Semaglutide — the GLP-1 specialist. Activates one receptor: GLP-1. It slows gastric emptying, reduces appetite at the source in the hypothalamus, and quiets the food-reward loop. It’s the most widely studied GLP-1 agonist in the world, with the deepest body of clinical evidence.
- Tirzepatide — the dual agonist. Activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The GIP pathway adds a second metabolic lever — influencing insulin sensitivity and how the body handles fat storage. In published clinical trials, dual agonism has generally produced greater average body-weight reduction than GLP-1 agonism alone, though individual responses vary widely.
THE ONE-SENTENCE VERSION
Semaglutide is the proven specialist working one pathway; tirzepatide works two pathways at once — and neither is universally “better,” because bodies respond individually.
How they compare, factor by factor
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP agonist |
| Dosing | Once-weekly injection, titrated | Once-weekly injection, titrated |
| Evidence base | Largest, longest track record | Newer; strong and growing trial data |
| Common side effects | Nausea, constipation, fatigue — usually early and transient | Similar profile; some patients report milder GI effects, others don’t |
| Branded versions | Ozempic®, Wegovy® | Mounjaro®, Zepbound® |
| CoraDoc program | From $99/month | From $149/month |
Not sure which one fits your body?
That’s exactly what your free physician visit decides. A licensed U.S. doctor reviews your history, goals, and health profile — and recommends the right starting point.
How a physician actually chooses between them
- Your metabolic picture. Insulin resistance, blood sugar patterns, and family history can favor the dual-pathway approach; a straightforward appetite-driven picture may respond fully to semaglutide.
- Budget and value. Semaglutide at $99/month is the most cost-efficient entry point; tirzepatide’s second mechanism justifies its $149 for many patients. Both include titration, oversight, and the Triple Free Promise at CoraDoc.
- Side-effect sensitivity. Individual GI tolerance differs by medication in ways that can’t be predicted in advance — a provider monitors and adjusts.
- Response over time. This is the part most people miss: the choice isn’t permanent. Patients who plateau on semaglutide sometimes break through after switching to tirzepatide — and your provider can switch you within your program based on real response data.
THE HONEST ANSWER
There is no universal winner. There’s the right medication for your biology, your budget, and your response — and the only way to find it is a physician who monitors and adjusts. Genetics play a real role in why responses differ; we cover that in our guide to GLP-1 genetics.
Related reading: Why GLP-1 works differently for different people · Your first 30 days on a GLP-1 · What to ask before starting a compounded GLP-1
What CoraDoc programs include
Licensed physician oversight throughout your program · dosage adjustments as your body changes · ongoing care-team support by real humans · compounded semaglutide from $99/mo or compounded tirzepatide from $149/mo · free visit, free shipping, free supplies.
✓ Doctor-prescribed ✓ All 50 states ✓ LegitScript certified ✓ No subscription
Semaglutide from $99/mo · Tirzepatide from $149/mo
Free doctor visit · dose increases included · switch medications with provider guidance · no subscription.
Compounded tirzepatide and semaglutide are not reviewed or approved by the FDA for safety, efficacy, or manufacturing quality and are not the same as branded medications. Prescriptions are issued only if a licensed provider determines a program is appropriate for you. Individual results vary. Mounjaro®, Zepbound®, Ozempic®, and Wegovy® are trademarks of their respective owners; CoraDoc is not affiliated with or endorsed by Eli Lilly or Novo Nordisk.
Frequently asked questions
Is tirzepatide stronger than semaglutide?
In published clinical trials, tirzepatide’s dual GLP-1 + GIP mechanism has generally produced greater average body-weight reduction than semaglutide’s single-pathway action — but individual responses vary widely, and some patients respond better to semaglutide. A licensed physician matches the medication to your biology.
Can I switch from semaglutide to tirzepatide?
Yes. Switching is a routine clinical decision made with your provider based on your response. CoraDoc patients can switch medications within their program with physician guidance — no restart required.
How much do tirzepatide and semaglutide cost at CoraDoc?
Compounded semaglutide programs start at $99/month and compounded tirzepatide at $149/month — six-month doctor-guided programs with the free provider visit, dose increases, 2-day cold shipping, and supplies included. No subscription.
Which one should I start with?
There’s no universal answer — it depends on your metabolic profile, budget, side-effect sensitivity, and goals. Your free CoraDoc consultation exists precisely to answer this question for your body.
Educational only — not medical advice. This guide is for general information and is not a substitute for consultation with a licensed healthcare provider. It does not diagnose, treat, or guarantee any outcome. Statistics cited are approximate and drawn from published clinical literature.
Prescription products are dispensed only if a licensed provider determines they’re appropriate for you. Certain medications offered through CoraDoc are compounded and are not reviewed or approved by the FDA for safety, efficacy, or manufacturing quality. Semaglutide and tirzepatide are not for everyone; potential side effects should be discussed with a provider. Individual results vary.